Moderna Stock Plummets as 2025 Sales Forecast Cut by $1 Billion Amid Vaccine Challenges
• 1 min read
Moderna's shares dropped 17% following a $1 billion reduction in its 2025 revenue forecast, driven by declining Covid vaccine market share and lower vaccination rates. The biotech company plans aggressive cost-cutting measures while maintaining optimism about its future product pipeline.